Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
|Articles|May 12, 2023
Things To Do in San Francisco While You Are Visiting for the 2023 APA Annual Meeting
Author(s)Leah Kuntz
Here are some things to check out in the city while you're in town...
Advertisement
Advertisement
Related to this article
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5